Regionale Hyperthermie kombiniert mit Chemoradiotherapie bei Erstdiagnose oder Rezidiv eines primären oder rezidivierten lokal fortgeschrittenen Pankreaskarzinoms: eine offene Kohortenvergleichsstudie

Maluta, S.; Schaffer, Moshe; Pioli, Fabio; Dall’Oglio, Stefano; Pasetto, Stefano; Schaffer, Pamela; Weber, B.; Giri, Maria Grazia

doi:10.1007/s00066-011-2226-6

Cited by 32 publications

(38 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the first and second selection (Figure 1), 14 studies were included [53][54][55][56][57][58][59][60][61][62][63][64][65][66]. Two patient cohorts were each described in two articles; for these we excluded the oldest [67,68] and included the latest [54,57].…”

Section: Literature Searchmentioning

confidence: 99%

“…The included 14 studies combined 395 pancreatic cancer patients of whom 248 received HT (Table 1). Six out of 14 studies used a control population that enabled a comparison between treatments with and without hyperthermia [54,55,57,60,62,66]. In two studies, patients with a variety of carcinomas were included, but data were reported for the pancreatic patients separately [53,59].…”

Section: Literature Searchmentioning

confidence: 99%

“…For the patients who received HT within the studies, this HT was in combination with radiotherapy for 17 patients (7%, two studies) [53,55], with chemoradiotherapy for 82 patients (33%, four studies) [54,60,62,66], and with chemotherapy for 149 patients (60%) in the remaining eight studies. Three types of hyperthermia treatment were applied: locoregional, whole-body and intraoperative hyperthermia.…”

Section: Patient Characteristics and Treatment Regimensmentioning

confidence: 99%

“…Locoregional hyperthermia was used in eight studies, with heating of tumour and surrounding tissue either radiative (using radiofrequency waves; 63 patients) [62,64] or capacitive (using electrodes; 126 patients) [53,58,60,63,65,66]. Treatment times varied from 40-60 min.…”

Section: Patient Characteristics and Treatment Regimensmentioning

confidence: 99%

See 3 more Smart Citations

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

Horst

Versteijne

Besselink

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

Objective: In pancreatic cancer, which is therapy resistant due to its hypoxic microenvironment, hyperthermia may enhance the effect of radio(chemo)therapy. The aim of this systematic review is to investigate the validity of the hypothesis that hyperthermia added to radiotherapy and/or chemotherapy improves treatment outcome for pancreatic cancer patients. Methods and materials: We searched MEDLINE and Embase, supplemented by handsearching, for clinical studies involving hyperthermia in pancreatic cancer patients. The quality of studies was evaluated using the Oxford Centre for Evidence-Based Medicine levels of evidence. Primary outcome was treatment efficacy; we calculated overall response rate and the weighted estimate of the population median overall survival (m p ) and compared these between hyperthermia and control cohorts. Results: Overall, 14 studies were included, with 395 patients with locally advanced and/or metastatic pancreatic cancer of whom 248 received hyperthermia. Patients were treated with regional (n ¼ 189), intraoperative (n ¼ 39) or whole-body hyperthermia (n ¼ 20), combined with chemotherapy, radiotherapy or both. Quality of the studies was low, with level of evidence 3 (five studies) and 4. The six studies including a control group showed a longer m p in the hyperthermia groups than in the control groups (11.7 vs. 5.6 months). Overall response rate, reported in three studies with a control group, was also better for the hyperthermia groups (43.9% vs. 35.3%). Conclusions: Hyperthermia, when added to chemotherapy and/or radiotherapy, may positively affect treatment outcome for patients with pancreatic cancer. However, the quality of the reviewed studies was limited and future randomised controlled trials are needed to establish efficacy. ARTICLE HISTORY

show abstract

Section: Literature Searchmentioning

confidence: 99%

Section: Literature Searchmentioning

confidence: 99%

Section: Patient Characteristics and Treatment Regimensmentioning

confidence: 99%

Section: Patient Characteristics and Treatment Regimensmentioning

confidence: 99%

See 2 more Smart Citations

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

Horst

Versteijne

Besselink

et al. 2017

International Journal of Hyperthermia

View full text Add to dashboard Cite

show abstract

“…The Italian Trial (Maluta et al 2011) [31] Underlying is a combination treatment of radiation (from 30 Gy/10 fractions to 66 Gy/33 fractions) with chemotherapy (CT). CT consisted of gemcitabine alone or in association with either oxaliplatin, cisplatin or 5-FU.…”

Section: The German Study I (Hager Et Al 2006) [24]mentioning

confidence: 99%

Review: The Role of Hyperthermia in Treating Pancreatic Tumors

Roesch

Mueller-Huebenthal

2014

Indian J Surg Oncol

View full text Add to dashboard Cite

There is only marginal improvement in outcome of treating pancreatic cancer in the last two decades. Time to open up and have a fresh look at complementary adjuvant treatment options. Hyperthermia may be one such option. Hyperthermic intraperitoneal chemotherapy (HIPEC) predominantly as a intrasurgical procedure has already proved its justification. Non-invasive loco regional hyperthermia as complement to either chemo or radiation has not yet reached a comparable status of evidence. However the potential to eventually grow into such evidence is already clearly observable. This review presents the various methodologies available for hyperthermia, covers the initial clinical data that has been published and gives an outlook to what can be expected in the next 2-3 years to come. Hyperthermia has the potential to significantly prolong life expectancies and this while maintaining a satisfying quality of life!

show abstract

Feasibility of ultrasound tomography–guided localized mild hyperthermia using a ring transducer: Ex vivo and in silico studies

et al. 2022

View full text Add to dashboard Cite

Background As of 2022, breast cancer continues to be the most diagnosed cancer worldwide. This problem persists within the United States as well, as the American Cancer Society has reported that ∼12.5% of women will be diagnosed with invasive breast cancer over the course of their lifetime. Therefore, a clinical need continues to exist to address this disease from a treatment and therapeutic perspective. Current treatments for breast cancer and cancers more broadly include surgery, radiation, and chemotherapy. Adjuncts to these methods have been developed to improve the clinical outcomes for patients. One such adjunctive treatment is mild hyperthermia therapy (MHTh), which has been shown to be successful in the treatment of cancers by increasing effectiveness and reduced dosage requirements for radiation and chemotherapies. MHTh‐assisted treatments can be performed with invasive thermal devices, noninvasive microwave induction, heating and recirculation of extracted patient blood, or whole‐body hyperthermia with hot blankets. Purpose One common method for inducing MHTh is by using microwave for heat induction and magnetic resonance imaging for temperature monitoring. However, this leads to a complex, expensive, and inaccessible therapy platform. Therefore, in this work we aim to show the feasibility of a novel all‐acoustic MHTh system that uses focused ultrasound (US) to induce heating while also using US tomography (UST) to provide temperature estimates. Changes in sound speed (SS) have been shown to be strongly correlated with temperature changes and can therefore be used to indirectly monitor heating throughout the therapy. Additionally, these SS estimates allow for heterogeneous SS‐corrected phase delays when heating complex and heterogeneous tissue structures. Methods Feasibility to induce localized heat in tissue was investigated in silico with a simulated breast model, including an embedded tumor using continuous wave US. Here, both heterogenous acoustic and thermal properties were modeled in addition to blood perfusion. We further demonstrate, with ex vivo tissue phantoms, the feasibility of using ring‐based UST to monitor temperature by tracking changes in SS. Two phantoms (lamb tissue and human abdominal fat) with latex tubes containing varied temperature flowing water were imaged. The measured SS of the water at each temperature were compared against values that are reported in literature. Results Results from ex vivo tissue studies indicate successful tracking of temperature under various phantom configurations and ranges of water temperature. The results of in silico studies show that the proposed system can heat an acoustically and thermally heterogenous breast model to the clinically relevant temperature of 42°C while accounting for a reasonable time needed to image the current cross section (200 ms). Further, we have performed an initial in silico study demonstrating the feasibility of adjusting the transmit waveform frequency to modify the effective heating height at the focused region. ...

show abstract

Regionale Hyperthermie kombiniert mit Chemoradiotherapie bei Erstdiagnose oder Rezidiv eines primären oder rezidivierten lokal fortgeschrittenen Pankreaskarzinoms: eine offene Kohortenvergleichsstudie

Abstract: HT can be added safely to CRT in LAPC, thus, resulting in slightly prolonged survival in certain cases.

Cited by 32 publications

References 36 publications

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

The clinical benefit of hyperthermia in pancreatic cancer: a systematic review

Review: The Role of Hyperthermia in Treating Pancreatic Tumors

Feasibility of ultrasound tomography–guided localized mild hyperthermia using a ring transducer: Ex vivo and in silico studies

Contact Info

Product

Resources

About